MAIA Biotechnology Files $150M Mixed Shelf Offering
https://www.sec.gov/Archives/edgar/data/1878313/000149315226039679/forms-3.htm
Stocks · News reference
MAIA Biotechnology Opens Enrollment For Phase 2 Expansion Trial Of MAIA's Lead Investigational Telomere-Targeting Agent Ateganosine As A Third-Line Treatment For Non-Small Cell Lung Cancer
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 27.78 percent increase over losses of $(0.18) per share
MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer